Descripción Componentes De Pantalla

When public health leaders consider future research and program goals to reduce HIV incidence, considering the individual needs of program recipients is

important. Many people who would initially take pre-exposure chemoprophylaxis would likely not be good candidates to continue the medication for their entire lives. As risk

38 factors for HIV infection change during their lifetimes, patients and their healthcare providers may decide taking pre-exposure chemoprophylaxis is not in the patient’s best interest at that time. Considering the frequency of individuals’ exposure to HIV,

researching options for pre-exposure chemoprophylaxis to better fit into the lifestyle of the recipients yet still be effective is worth consideration for government funding. Effective public health leaders who regularly review and evaluate program data and available data sets of community HIV prevalence and incidence rates may find they are better equipped to propose new areas for research to fill HIV prevention gaps.

Hermann Briggs once noted, “Public Health is purchasable. Within natural limitations every community can determine its own death rate” (Gostin, 2000). Briggs expressed this notion in 1894 (Gostin, 2000), many years before the discovery of HIV and the start of the pandemic which has claimed lives in every community across the globe. The choice to provide affordable pre-exposure chemoprophylaxis for women who have no other options for HIV prevention is the responsibility of leaders in public health, government officials, donors, and anyone who elects a public leader.

39 References

Abbas, U. L., Anderson, R. M., & Mellors, J. W. (2007). Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One, 2(9), 875.

Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., . . . and on behalf of the CAPRISA 004 Trial Group. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329(5996), 1168.

Achmat, Z. (2006). Make truth powerful: Leadership in science, prevention and the treatment of HIV/AIDS. Closing address presented at the 2006 International Microbicides Conference, Cape Town, South Africa. Address retrieved from http://www.tig.org.za/pdf-files/affidavit-

Qaaug06/62A%20Achmat%20at%20Microbiocides%202006%20conference.pdf Anton, P. (2011). RMP-02/MTN-006: A phase 1 placebo-controlled trial of rectally

applied 1% vaginal TFV gel with comparison to oral TDF. Oral abstract presented at the 18th Conference of Retroviruses and Opportunistic Infections, Boston, MA. Audio webcast retrieved from

http://www.retroconference.org/2011/data/files/webcast_2011.htm

Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Medicine, 2(11), 1112.

Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., . . . Ndinya- Achola, J. O. (2007). Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. The Lancet, 369(9562), 643-656.

40 Beauchamp, T. L., & Childress, J. F. (2001). Chapter 6: Justice. In Principles of

biomedical ethics (5th Edition ed., pp. 225) Oxford University Press, USA. Bhattacharya, G. (2004). Sociocultural and behavioral contexts of condom use in

heterosexual married couples in India: Challenges to the HIV prevention program. Health Education & Behavior, 31(1), 101.

Bouillon, K., Lert, F., Sitta, R., Schmaus, A., Spire, B., & Dray-Spira, R. (2007). Factors correlated with disclosure of HIV infection in the French Antilles and French Guiana: Results from the ANRS-EN13-VESPA-DFA study. AIDS (London, England), 21, S89.

Centers for Disease Control and Prevention. (2011). Morbidity and mortality weekly report: Interim guidance: Preexposure prophylaxis for the prevention of HIV

infection in men who have sex with men. No. 60 (03)). Atlanta: Centers for Disease Control.

DeGruttola, V., Smith, D. M., Little, S. J., & Miller, V. (2010). Developing and evaluating comprehensive HIV infection control strategies: Issues and challenges. Clinical Infectious Diseases, 50(Supplement 3), S102.

Desai, K., Sansom, S. L., Ackers, M. L., Stewart, S. R., Hall, H. I., Hu, D. J., . . . Boily, M. C. (2008). Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost- effectiveness. AIDS, 22(14), 1829.

Dworkin, R. (1992). Justice in the distribution of health care. McGill Law Journal, 38, 883.

41 Eagle, K. A., Garson, A. J., Beller, G. A., & Sennett, C. (2003). Closing the gap between

science and practice: The need for professional leadership. Health Affairs, 22(2), 196.

Forsythe, S., Stover, J., & Bollinger, L. (2009). The past, present and future of HIV, AIDS and resource allocation. BMC Public Health, 9(Suppl 1), S4.

García-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M., Masciotra, S., . . . Monsour, M. (2008). Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med, 5(2), e28. Gert, B., Culver, C. M., & Clouser, K. D. (2006). Morality. In Bioethics: A systematic

approach (Second ed., pp. 21-49) Oxford University Press, USA.

Gilead Sciences. (2011). Full prescribing information: Truvada. Retrieved March 2011, 2011, from http://www.truvada.com/pdf/fpi.pdf

Goleman, D., Boyatzis, R. E., & McKee, A. (2002). The new leaders: Transforming the art of leadership into the science of results Little, Brown.

Gostin, L. O. (2000). Chapter 1, A theory and definition of public health law. In Public health law: Power, duty, restraint ( pp. 3-24). Berkeley, California: University of California Press.

Gostin, L. O., & Taylor, A. L. (2008). Global health law: A definition and grand challenges. Public Health Ethics, 1(1), 53.

Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., . . . Ramirez-Cardich, M. E. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587- 2599.

42 Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., . . . Chen,

M. Z. (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. The Lancet, 369(9562), 657-666.

Hendrix, C. (2011). MTN-001: A phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product

acceptability and vaginal tissue drug concentrations. Oral abstract presented at the 18th Conference of Retroviruses and Opportunistic Infections, Boston, MA. Audio webcast retrieved from

http://www.retroconference.org/2011/data/files/webcast_2011.htm

Holland, S. M. (2007). Public health ethics (2nd ed.). Malden, MA: Polity Press.

Johnston, M. I., & Fauci, A. S. (2008). An HIV vaccine--challenges and prospects. New England Journal of Medicine, 359(9), 888.

Joint United Nations Programme on HIV/AIDS. (2010). Report on the global HIV/AIDS epidemic Joint United Nations Programme on HIV/AIDS.

Kaler, A. (2001). “It’s some kind of women’s empowerment”: The ambiguity of the female condom as a marker of female empowerment. Social Science & Medicine, 52(5), 783-796.

Kass, N. E. (2001). An ethics framework for public health. American Journal of Public Health, 91(11), 1776.

Kenyon, C., Boulle, A., Badri, M., & Asselman, V. (2010). “I don’t use a condom (with my regular partner) because I know that I’m faith-ful, but with everyone else I do”: The cultural and socioeconomic determinants of sexual partner concurrency in young South Africans. Journal of Social Aspects of HIV/AIDS, 7(3).

43 Liu, A. Y., Grant, R. M., & Buchbinder, S. P. (2006). Preexposure prophylaxis for HIV:

Unproven promise and potential pitfalls. JAMA, 296(7), 863.

Lurie, P., Miller, S., Hecht, F., Chesney, M., & Lo, B. (1998). Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical, and policy considerations. JAMA, 280(20), 1769.

Martin, J. N., Roland, M. E., Neilands, T. B., Krone, M. R., Bamberger, J. D., Kohn, R. P., . . . Coates, T. J. (2004). Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS, 18(5), 787.

Matthews, L. T., Baeten, J. M., Celum, C., & Bangsberg, D. R. (2010). Periconception pre-exposure prophylaxis to prevent HIV transmission: Benefits, risks, and

challenges to implementation. AIDS, 24(13), 1975.

Mayer, K., Mimiaga, M., White, J., Krakower, D., & Vanderwarker, R. (2011).

Knowledge, attitudes, and beliefs of Massachusetts physicians regarding topical and oral antiretroviral chemoprophylaxis. Poster abstract presented at the 18th

Conference of Retroviruses and Opportunistic Infections, Boston, MA. Abstract retrieved from http://www.retroconference.org/2011/Abstracts/41043.htm

Mayer, K. H., & Venkatesh, K. K. (2010). Chemoprophylaxis for HIV prevention: New opportunities and new questions. JAIDS Journal of Acquired Immune Deficiency Syndromes, 55, S122.

National Public Health Leadership Development Network. (2005). Public health leadership competency framework. Retrieved from

44 Novotny, T. E. (2006). US department of health and human services: A need for global

health leadership in preparedness and health diplomacy. American Journal of Public Health, 96(1), 11.

Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., . . . Walensky, R. P. (2009). HIV pre-exposure prophylaxis (PrEP) in the United

States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 48(6), 806.

Park, J. (2011). Cost effectiveness of PrEP for HIV infection in South Africa. Oral abstract presented at the 18th Conference of Retroviruses and Opportunistic Infections, Boston, MA. Audio webcast retrieved from

http://www.retroconference.org/2011/data/files/webcast_2011.htm

Peters, T. (2001). Leadership: Sad facts and silver linings. HBR, 79(11) 121-28. Pretorius, C., Stover, J., Bollinger, L., Bacaër, N., Williams, B., & Myer, L. (2010).

Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in south africa. PLoS One, 5(11), 96-101.

Public Health Leadership Society. (2002). Principles of the ethical practice of public health, version 2.2. Retrieved from http://www.apha.org/NR/rdonlyres/1CED3CEA- 287E-4185-9CBD-BD405FC60856/0/ethicsbrochure.pdf

Public Health Foundation, The Council on Linkages Between Academia and Public Health Practice. (2010). Core competencies for public health professionals. Retrieved from

45 http://www.phf.org/resourcestools/Documents/Core_Public_Health_Competencies_II I.pdf

Quinn, T. C., & Overbaugh, J. (2005). HIV/AIDS in women: An expanding epidemic. Science, 308(5728), 1582.

Roper, W. L., Peterson, H. B., & Curran, J. W. (1993). Commentary: Condoms and HIV/STD prevention--clarifying the message. American Journal of Public Health, 83(4), 501.

Schechter, M., do Lago, R. F., Mendelsohn, A. B., Moreira, R. I., Moulton, L. H., & Harrison, L. H. (2004). Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes, 35(5), 519.

Shannon, K., Strathdee, S. A., Shoveller, J., Gobson, K., Kerr, T., & Tyndall, M. W. (2009). Structural and environmental barriers to condom use negotiation with clients among women in survival sex work: Implications for HIV prevention and policy. Am J Public Health, 99, 659-665.

Shelton, J. D., Halperin, D. T., Nantulya, V., Potts, M., Gayle, H. D., & Holmes, K. K. (2004). Partner reduction is crucial for balanced “ABC” approach to HIV prevention. BMJ, 328(7444), 891.

van Griensven, F., Thienkrua, W., Sukwicha, W., Wimonsate, W., Chaikummao, S., Varangrat, A., & Mock, P. A. (2010). Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: Implications for pre-and post- exposure prophylaxis against HIV infection. Journal of the International AIDS Society, 13, 13.

46 Vissers, D. C. J., Voeten, H. A. C. M., Nagelkerke, N. J. D., Habbema, J. D. F., & de

Vlas, S. J. (2008). The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One, 3(5), 2077.

Wang, L., Shan, D., Chan, S., Chen, H., Ge, Z., Ding, G., . . . Liu, Z. (2010). Disclosure of HIV-positive serostatus to sexual partners and associated factors in southern China. International Journal of STD & AIDS, 21(10), 685.

Watters, J. K., Estilo, M. J., Clark, G. L., & Lorvick, J. (1994). Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA, 271(2), 115. Wegbreit, J., Bertozzi, S., DeMaria, L. M., & Padian, N. S. (2006). Effectiveness of HIV

prevention strategies in resource-poor countries: Tailoring the intervention to the context. AIDS, 20(9), 1217.